TICKERNERD
Menu
VRTXVRTXHealthcare · Biotechnology

VRTX Stock Forecast: Vertex Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 25 Aug 2026
$553
+0.96% on the day

The 28 Wall Street analysts covering Vertex Pharmaceuticals, Inc. hold a median 12-month price target of $568 — +2.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 24 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$138.9B
Ticker Nerd rank
71 / 100
Median analyst target
$568
Analysts covering
28
Revenue$3.3B+12.5% y/y
Operating income$1.3B
Net income$1.1B
Free cash flow$1.0B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.7%
1M
+15.8%
YTD
+21.9%
1Y
+42.1%
From 52W high
0.0%
From 52W low
+46.8%
$377
$553
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VRTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vertex Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Aug 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
98
Quality
92
Momentum
64
Growth
62
Issuance
59
Revisions
56
Accruals
27
Size
2

Volatility (99): The share price has been relatively steady.

Accruals (27): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VRTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VRTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$300$400$500$600$700Oct 25Jan 26Apr 26Jul 26VRTXHigh $672Median $568Low $350

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
22 Buy4 Hold2 Sell
Low $350Median $568High $672

The green dot is the last close — the median target sits +2.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
5 Aug 2026BarclaysMaintainsOverweight$615 → $617
5 Aug 2026Truist SecuritiesMaintainsBuy$560 → $565
4 Aug 2026Canaccord GenuityMaintainsHold$436 → $442
4 Aug 2026Cantor FitzgeraldMaintainsOverweight$590 → $595
4 Aug 2026TD CowenMaintainsBuy$525 → $550
13 July 2026Truist SecuritiesMaintainsBuy$542 → $560
13 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026UBSMaintainsBuy$545 → $585
13 July 2026UBSMaintainsBuy—
7 July 2026BairdMaintainsUnderperform$330 → $350
7 July 2026BairdMaintainsUnderperform—
7 July 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$543 → $570
6 May 2026BarclaysMaintainsOverweight—
5 May 2026BernsteinMaintainsOutperform—
5 May 2026Canaccord GenuityMaintainsHold—
5 May 2026Morgan StanleyMaintainsOverweight—
5 May 2026RBC CapitalMaintainsOutperform—
30 Apr 2026Canaccord GenuityMaintainsHold—
10 Apr 2026Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VRTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 25 Aug 2026, Vertex Pharmaceuticals, Inc. returned +42.1% against +20.5% for the S&P 500, dividends included.

VRTX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Oct 25Jan 26Apr 26Jul 26VRTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VRTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.5%
Analysts raising
7
Analysts cutting
7
Fundamentals

Vertex Pharmaceuticals, Inc. (VRTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
32.0×

Cheaper than 25% of US stocks

Price / sales
11.0×

Cheaper than 14% of US stocks

Price / book
6.9×

Cheaper than 16% of US stocks

EV / EBITDA
26.1×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
12.5%

Higher than 58% of US stocks

Earnings growth (YoY)
6.5%

Higher than 43% of US stocks

Gross margin
85.3%

Higher than 94% of US stocks

Operating margin
38.1%

Higher than 91% of US stocks

Net margin
35.0%

Higher than 92% of US stocks

Returns & dividend
Return on equity
23.5%

Higher than 84% of US stocks

Return on assets
11.9%

Higher than 95% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vertex Pharmaceuticals, Inc. (VRTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vertex Pharmaceuticals, Inc. has a market value of $138.9B and an enterprise value of $133.0B.

  • Revenue in the twelve months to 30 June 2026: $12.6B. The latest quarter grew 12.5% year on year.

  • Net income over the same four quarters: $4.4B, a 35.0% net margin.

  • Diluted earnings per share, trailing twelve months: $17.18.

  • Free cash flow in the twelve months to 30 June 2026: $3.8B.

  • Vertex Pharmaceuticals, Inc. spent $2.3B on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 253.3M.

  • Trailing P/E: 32.0×; forward P/E: 24.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Vertex Pharmaceuticals, Inc. employs 6,400 people — $2.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

VRTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VRTXVertex Pharmaceuticals, Inc.$138.9B
71
REGNRegeneron Pharmaceuticals, Inc.$87.1B
93
MRNAModerna, Inc.$55.4B
78
RVMDRevolution Medicines, Inc.$44.2B
36
RPRXRoyalty Pharma plc$35.3B
86
ALNYAlnylam Pharmaceuticals, Inc.$31.2B
56
INSMInsmed, Inc.$27.1B
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vertex Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VRTX news & analysis

Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside?

The Motley Fool · 21 Aug 2026positive

The Motley Fool published a Scoreboard episode featuring its contributing expert analysts discussing Vertex Pharmaceuticals. The piece is a video aimed at providing insights into market trends and potential investment opportunities related to the company.

Why it matters — A Vertex watcher would care because the episode offers analyst perspectives on the company's market positioning and pipeline, which could inform their view of its prospects.

Uber, ServiceNow And A Health Care Stock On CNBC's ‘Final Trades'

Benzinga · 21 Aug 2026neutral

CNBC's "Halftime Report Final Trades" segment featured picks including Uber, ServiceNow, and a health care stock, with NewEdge Wealth CEO Rob Sechan choosing ServiceNow. Vertex Pharmaceuticals was not specifically discussed in the segment.

Why it matters — While Vertex is not mentioned in this segment, the health care stock included in the final trades discussion may be of interest to those tracking the sector.

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

The Motley Fool · 20 Aug 2026positive

A key potential competitor to Vertex Pharmaceuticals in its core market recently suffered a clinical setback, easing a competitive threat to the company's business. Wall Street reportedly sees continued upside for Vertex following the development.

Why it matters — VRTX watchers would care because reduced competition in the company's core market could help protect its existing revenue franchise.

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Business Wire · 17 Aug 2026neutral

Law firm Kahn Swick & Foti, LLC is investigating the proposed sale of Crinetics Pharmaceuticals, Inc. to Vertex Pharmaceuticals Incorporated, in which Crinetics shareholders would receive $85.00 in cash per share. KSF is seeking to determine whether this consideration and the deal process are adequate.

Why it matters — VRTX watchers would care because the investigation examines the price and process of Vertex's proposed acquisition of Crinetics, which could affect how the transaction proceeds.

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The Motley Fool · 14 Aug 2026positive

Vertex Pharmaceuticals hit an all-time high and is seen as likely to continue dominating its core therapeutic area while slowly developing and launching medicines in other markets.

Why it matters — VRTX watchers would care because the company appears positioned to sustain strength in its core franchise while gradually expanding into new therapeutic areas.

FAQ

Frequently asked questions about VRTX stock

What is the VRTX stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Vertex Pharmaceuticals, Inc. have a median 12-month price target of $568, with estimates ranging from $350 to $672. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VRTX stock a buy right now?

Of the 28 analysts covering Vertex Pharmaceuticals, Inc., 22 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Vertex Pharmaceuticals, Inc. 71 out of 100 across roughly 4,600 US stocks as at 24 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VRTX?

As at 24 Aug 2026, Vertex Pharmaceuticals, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will VRTX stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +2.6% from the last close, and Ticker Nerd's factor model ranks Vertex Pharmaceuticals, Inc. 71 out of 100 as at 24 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VRTX stock forecast for 2030?

No analyst covering Vertex Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $350 to $672 over the next 12 months.

How has VRTX stock performed over the past year?

Vertex Pharmaceuticals, Inc. returned +42.1% over the 12 months to 25 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vertex Pharmaceuticals, Inc. do?

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative medicines for serious diseases. The company is best known for its leadership in cystic fibrosis, where it markets a portfolio of CFTR modulator therapies such as Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco and Alyftrek that address underlying genetic defects in eligible patients across multiple age groups.

What is the latest news on VRTX?

The most recent item we track (The Motley Fool, 21 Aug 2026): "Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside?". The Motley Fool published a Scoreboard episode featuring its contributing expert analysts discussing Vertex Pharmaceuticals. The piece is a video aimed at providing insights into market trends and potential investment opportunities related to the company.

Company

About Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative medicines for serious diseases. The company is best known for its leadership in cystic fibrosis, where it markets a portfolio of CFTR modulator therapies such as Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco and Alyftrek that address underlying genetic defects in eligible patients across multiple age groups. Beyond cystic fibrosis, Vertex today provides and develops treatments for sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain, as well as investigational therapies for APOL1-mediated kidney disease and other severe conditions. Headquartered in Boston, Massachusetts and founded in 1989, Vertex operates across the United States, Europe, and internationally, serving specialized markets through a combination of proprietary drug development, advanced research collaborations, and global commercialization capabilities. Its portfolio positions the company as a key player in specialty care within the broader healthcare and biotechnology sectors.

CEO Dr. Reshma Kewalramani FASN, M.D. · 6,400 employees · United States · https://www.vrtx.com